Journey Medical (DERM) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
1 May, 2026Voting matters and shareholder proposals
Shareholders will vote on the election of six directors for the upcoming term, with all nominees recommended by the board.
Proposal to ratify KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Board of directors and corporate governance
Six director nominees are presented for election, including Lindsay A. Rosenwald, M.D., Claude Maraoui, Neil Herskowitz, Justin Smith, Miranda Toledano, and Michael Pearce.
Audit committee and external auditor matters
KPMG LLP is proposed for ratification as the external auditor for the next fiscal year, with board recommendation in favor.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Journey Medical
- Q2 2026 revenue rose 23% to $18.5M, with Emrosi/EMROSI driving growth and net loss narrowing.DERM
Q2 2026 - Emrosi®'s clinical and commercial success positions it as the leading oral rosacea therapy.DERMInvestor presentation
- All director nominees and KPMG as auditors for 2026 were approved; Q&A followed.DERMAGM 2026
- EMROSI drives rapid growth, with rising revenue, margins, and expanded market access.DERMA.G.P.'s Annual Virtual Healthcare Conference
- Q1 2026 revenue up 21% to $16M, net loss narrows, and EMROSI/Emrosi® expands market access.DERMQ1 2026
- Emrosi® drives revenue growth as the leading oral rosacea therapy, with expanding market access.DERMInvestor presentation
- Virtual meeting to elect directors, ratify auditor, and review governance and compensation.DERMProxy filing
- Q2 revenue rose sequentially, profitability improved, and DFD-29 FDA review is pending.DERMQ2 2024
- Emrosi FDA approval and launch set the stage for transformational growth in 2025.DERMQ4 2024